Jeffrey F Scherrer1,2, John E Morley3, Joanne Salas4,2, James S Floyd5,6,7, Susan A Farr3,8, Sascha Dublin5,9. 1. Department of Family and Community Medicine, Saint Louis University School of Medicine, St Louis, Missouri jeffrey.scherrer@health.slu.edu. 2. Harry S. Truman Veterans Administration Medical Center, Research Service, Columbia, Missouri. 3. Division of Geriatric Medicine, Saint Louis University School of Medicine, St Louis, Missouri. 4. Department of Family and Community Medicine, Saint Louis University School of Medicine, St Louis, Missouri. 5. Department of Epidemiology, University of Washington, Seattle, Washington. 6. Department of Medicine, University of Washington, Seattle, Washington. 7. Cardiovascular Health Research Unit, University of Washington, Seattle, Washington. 8. Saint Louis Veterans Affairs Medical Center, Research Service, John Cochran Division, St Louis, Missouri. 9. Kaiser Permanente Washington Health Research Institute, Seattle, Washington.
Abstract
PURPOSE: African American patients are more likely to experience cognitive decline after type 2 diabetes mellitus onset than white patients. Metformin use has been associated with a lower risk of dementia compared with sulfonylureas. Evidence for whether this association differs by race is sparse. METHODS: Veterans Health Administration (VHA) medical record data were obtained for 73,761 African American and white patients aged ≥50 years who used the VHA from fiscal years 2000 to 2015. Patients were free of dementia and diabetes medications during fiscal years 2000 and 2001 and subsequently initiated metformin or sulfonylurea monotherapy. For race and age subgroups, Cox proportional hazards models using propensity scores and inverse probability of treatment weighting to control for confounding were computed to measure the association between metformin vs sulfonylurea initiation and incident dementia. RESULTS: After controlling for confounding, among patients aged ≥50 years, metformin vs sulfonylurea use was associated with a significantly lower risk of dementia in African American patients (hazard ratio [HR] = 0.73; 95% CI, 0.6-0.89) but not white patients (HR = 0.96; 95% CI, 0.9-1.03). The strongest magnitude of association between metformin and dementia was observed among African American patients aged 50 to 64 years (HR = 0.6; 95% CI, 0.45-0.81). Among those aged 65 to 74 years, metformin was significantly associated with lower risk of dementia in both races. Metformin was not associated with dementia in patients aged ≥75 years. CONCLUSIONS: Metformin vs sulfonylurea initiation was associated with a substantially lower risk of dementia among younger African American patients. These results may point to a novel approach for reducing the risk of dementia in African Americans with type 2 diabetes mellitus.
PURPOSE: African American patients are more likely to experience cognitive decline after type 2 diabetes mellitus onset than white patients. Metformin use has been associated with a lower risk of dementia compared with sulfonylureas. Evidence for whether this association differs by race is sparse. METHODS: Veterans Health Administration (VHA) medical record data were obtained for 73,761 African American and white patients aged ≥50 years who used the VHA from fiscal years 2000 to 2015. Patients were free of dementia and diabetes medications during fiscal years 2000 and 2001 and subsequently initiated metformin or sulfonylurea monotherapy. For race and age subgroups, Cox proportional hazards models using propensity scores and inverse probability of treatment weighting to control for confounding were computed to measure the association between metformin vs sulfonylurea initiation and incident dementia. RESULTS: After controlling for confounding, among patients aged ≥50 years, metformin vs sulfonylurea use was associated with a significantly lower risk of dementia in African American patients (hazard ratio [HR] = 0.73; 95% CI, 0.6-0.89) but not white patients (HR = 0.96; 95% CI, 0.9-1.03). The strongest magnitude of association between metformin and dementia was observed among African American patients aged 50 to 64 years (HR = 0.6; 95% CI, 0.45-0.81). Among those aged 65 to 74 years, metformin was significantly associated with lower risk of dementia in both races. Metformin was not associated with dementia in patients aged ≥75 years. CONCLUSIONS:Metformin vs sulfonylurea initiation was associated with a substantially lower risk of dementia among younger African American patients. These results may point to a novel approach for reducing the risk of dementia in African Americans with type 2 diabetes mellitus.
Authors: L Keoki Williams; Badri Padhukasahasram; Brian K Ahmedani; Edward L Peterson; Karen E Wells; Esteban González Burchard; David E Lanfear Journal: J Clin Endocrinol Metab Date: 2014-06-12 Impact factor: 5.958
Authors: Jeffrey F Scherrer; Joanne Salas; James S Floyd; Susan A Farr; John E Morley; Sascha Dublin Journal: Mayo Clin Proc Date: 2019-08 Impact factor: 7.616
Authors: Imad M El-Kebbi; Curtiss B Cook; David C Ziemer; Christopher D Miller; Daniel L Gallina; Lawrence S Phillips Journal: Arch Intern Med Date: 2003-01-13
Authors: Barbara N Harding; James S Floyd; Jeffrey F Scherrer; Joanne Salas; John E Morley; Susan A Farr; Sascha Dublin Journal: Healthc (Amst) Date: 2020-05-22
Authors: Mary Clare Masters; Jeremiah Perez; Kunling Wu; Ronald J Ellis; Karl Goodkin; Susan L Koletar; Adriana Andrade; Jingyan Yang; Todd T Brown; Frank J Palella; Ned Sacktor; Katherine Tassiopoulos; Kristine M Erlandson Journal: Clin Infect Dis Date: 2021-08-16 Impact factor: 20.999
Authors: Jeffrey F Scherrer; Joanne Salas; Timothy L Wiemken; Daniel F Hoft; Christine Jacobs; John E Morley Journal: PLoS One Date: 2021-11-17 Impact factor: 3.240
Authors: Timothy L Wiemken; Joanne Salas; John E Morley; Daniel F Hoft; Christine Jacobs; Jeffrey F Scherrer Journal: J Am Geriatr Soc Date: 2021-12-12 Impact factor: 7.538
Authors: Danielle Newby; Andrew Brent Linden; Marco Fernandes; Yasmina Molero; Laura Winchester; William Sproviero; Upamanyu Ghose; Qingqin S Li; Lenore J Launer; Cornelia M van Duijn; Alejo J Nevado-Holgado Journal: BMJ Open Diabetes Res Care Date: 2022-09
Authors: Jiahui Dai; Kayleen Deanna Ports; Maria M Corrada; Andrew O Odegaard; Joan O'Connell; Luohua Jiang Journal: J Alzheimers Dis Rep Date: 2022-08-03